Trial Outcomes & Findings for A Study of LY3405105 in Participants With Advanced Cancer (NCT NCT03770494)
NCT ID: NCT03770494
Last Updated: 2025-11-04
Results Overview
ORR is the best overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
Recruitment status
TERMINATED
Study phase
PHASE1
Target enrollment
54 participants
Primary outcome timeframe
Baseline through Measured Progressive Disease (Estimated up to 6 Months)
Results posted on
2025-11-04
Participant Flow
* Phase 1a was a dose escalation phase with a starting dose of LY3405105 1 milligram (mg) once daily (Part A1) or 2 mg three times per week (Part A2) on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason. Each dose level will have minimum of 3 participants enrolled. * Phase 1b was a dose expansion phase which was planned but not initiated based on sponsor's decision and limited efficacy observed in phase 1a. No participants enrolled.
Completers included participants who died from any cause.
Participant milestones
| Measure |
Part A1 Cohort 1 (1 mg, QD)
Participants received 1 mg LY3405105 once daily (QD) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 2 (2 mg, QD)
Participants received 2 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 3 (4 mg, QD)
Participants received 3 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 4 (8 mg, QD)
Participants received 8 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 5 (15 mg, QD)
Participants received 15 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 6 (30 mg, QD)
Participants received 30 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 7 (45 mg, QD)
Participants received 45 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 8 (35 mg, QD)
Participants received 35 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 9 (25 mg, QD)
Participants received 25 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 10 (20 mg, QD)
Participants received 20 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 1 (2 mg, TIW)
Participants received 2 mg LY3405105 three times per week (TIW) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 2 (4 mg, TIW)
Participants received 4 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 3 (8 mg, TIW)
Participants received 8 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Phase 1b
This is a dose-expansion phase designed to explore the anti-tumor activity of recommended LY3405105 dose and dosing schedule determined in phase 1a, in participants with multiple tumor types.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
4
|
4
|
4
|
4
|
5
|
5
|
5
|
3
|
3
|
6
|
4
|
4
|
3
|
0
|
|
Overall Study
Received At Least 1 Dose of Study Drug
|
4
|
4
|
4
|
4
|
5
|
5
|
5
|
3
|
3
|
6
|
4
|
4
|
3
|
0
|
|
Overall Study
COMPLETED
|
2
|
1
|
2
|
2
|
1
|
1
|
2
|
1
|
0
|
1
|
2
|
2
|
3
|
0
|
|
Overall Study
NOT COMPLETED
|
2
|
3
|
2
|
2
|
4
|
4
|
3
|
2
|
3
|
5
|
2
|
2
|
0
|
0
|
Reasons for withdrawal
| Measure |
Part A1 Cohort 1 (1 mg, QD)
Participants received 1 mg LY3405105 once daily (QD) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 2 (2 mg, QD)
Participants received 2 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 3 (4 mg, QD)
Participants received 3 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 4 (8 mg, QD)
Participants received 8 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 5 (15 mg, QD)
Participants received 15 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 6 (30 mg, QD)
Participants received 30 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 7 (45 mg, QD)
Participants received 45 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 8 (35 mg, QD)
Participants received 35 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 9 (25 mg, QD)
Participants received 25 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 10 (20 mg, QD)
Participants received 20 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 1 (2 mg, TIW)
Participants received 2 mg LY3405105 three times per week (TIW) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 2 (4 mg, TIW)
Participants received 4 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 3 (8 mg, TIW)
Participants received 8 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Phase 1b
This is a dose-expansion phase designed to explore the anti-tumor activity of recommended LY3405105 dose and dosing schedule determined in phase 1a, in participants with multiple tumor types.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Lost to Follow-up
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Study terminated by sponsor
|
1
|
2
|
1
|
1
|
1
|
2
|
1
|
2
|
1
|
2
|
1
|
2
|
0
|
0
|
|
Overall Study
Withdrawal by Subject
|
1
|
1
|
0
|
0
|
2
|
2
|
2
|
0
|
2
|
3
|
1
|
0
|
0
|
0
|
Baseline Characteristics
A Study of LY3405105 in Participants With Advanced Cancer
Baseline characteristics by cohort
| Measure |
Part A1 Cohort 1 (1 mg, QD)
n=4 Participants
Participants received 1 mg LY3405105 once daily (QD) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 2 (2 mg, QD)
n=4 Participants
Participants received 2 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 3 (4 mg, QD)
n=4 Participants
Participants received 3 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 4 (8 mg, QD)
n=4 Participants
Participants received 8 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 5 (15 mg, QD)
n=5 Participants
Participants received 15 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 6 (30 mg, QD)
n=5 Participants
Participants received 30 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 7 (45 mg, QD)
n=5 Participants
Participants received 45 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 8 (35 mg, QD)
n=3 Participants
Participants received 35 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 9 (25 mg, QD)
n=3 Participants
Participants received 25 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 10 (20 mg, QD)
n=6 Participants
Participants received 20 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 1 (2 mg, TIW)
n=4 Participants
Participants received 2 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 2 (4 mg, TIW)
n=4 Participants
Participants received 4 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 3 (8 mg, TIW)
n=3 Participants
Participants received 8 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Total
n=54 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=15 Participants
|
0 Participants
n=161 Participants
|
0 Participants
n=100 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=68 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
3 Participants
n=15 Participants
|
2 Participants
n=161 Participants
|
1 Participants
n=100 Participants
|
3 Participants
n=3 Participants
|
2 Participants
n=8 Participants
|
2 Participants
n=7 Participants
|
4 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=68 Participants
|
3 Participants
n=4 Participants
|
3 Participants
n=44 Participants
|
2 Participants
n=5 Participants
|
32 Participants
n=20 Participants
|
|
Age, Categorical
>=65 years
|
1 Participants
n=15 Participants
|
2 Participants
n=161 Participants
|
3 Participants
n=100 Participants
|
1 Participants
n=3 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=7 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=68 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=44 Participants
|
1 Participants
n=5 Participants
|
22 Participants
n=20 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=15 Participants
|
4 Participants
n=161 Participants
|
2 Participants
n=100 Participants
|
3 Participants
n=3 Participants
|
4 Participants
n=8 Participants
|
2 Participants
n=7 Participants
|
5 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
5 Participants
n=68 Participants
|
3 Participants
n=4 Participants
|
4 Participants
n=44 Participants
|
1 Participants
n=5 Participants
|
41 Participants
n=20 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=15 Participants
|
0 Participants
n=161 Participants
|
2 Participants
n=100 Participants
|
1 Participants
n=3 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=7 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=68 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=44 Participants
|
2 Participants
n=5 Participants
|
13 Participants
n=20 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=15 Participants
|
0 Participants
n=161 Participants
|
0 Participants
n=100 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=68 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=15 Participants
|
0 Participants
n=161 Participants
|
1 Participants
n=100 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=68 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=44 Participants
|
1 Participants
n=5 Participants
|
5 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
1 Participants
n=15 Participants
|
0 Participants
n=161 Participants
|
0 Participants
n=100 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=68 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=15 Participants
|
1 Participants
n=161 Participants
|
0 Participants
n=100 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=68 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=44 Participants
|
0 Participants
n=5 Participants
|
4 Participants
n=20 Participants
|
|
Race (NIH/OMB)
White
|
3 Participants
n=15 Participants
|
3 Participants
n=161 Participants
|
3 Participants
n=100 Participants
|
4 Participants
n=3 Participants
|
4 Participants
n=8 Participants
|
5 Participants
n=7 Participants
|
4 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
5 Participants
n=68 Participants
|
4 Participants
n=4 Participants
|
3 Participants
n=44 Participants
|
2 Participants
n=5 Participants
|
43 Participants
n=20 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=15 Participants
|
0 Participants
n=161 Participants
|
0 Participants
n=100 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=68 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=15 Participants
|
0 Participants
n=161 Participants
|
0 Participants
n=100 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=68 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=20 Participants
|
|
Region of Enrollment
Canada
|
0 Participants
n=15 Participants
|
1 Participants
n=161 Participants
|
1 Participants
n=100 Participants
|
1 Participants
n=3 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=68 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=5 Participants
|
7 Participants
n=20 Participants
|
|
Region of Enrollment
Spain
|
3 Participants
n=15 Participants
|
1 Participants
n=161 Participants
|
0 Participants
n=100 Participants
|
1 Participants
n=3 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=68 Participants
|
4 Participants
n=4 Participants
|
2 Participants
n=44 Participants
|
1 Participants
n=5 Participants
|
17 Participants
n=20 Participants
|
|
Region of Enrollment
United States
|
1 Participants
n=15 Participants
|
2 Participants
n=161 Participants
|
3 Participants
n=100 Participants
|
2 Participants
n=3 Participants
|
3 Participants
n=8 Participants
|
4 Participants
n=7 Participants
|
3 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
5 Participants
n=68 Participants
|
0 Participants
n=4 Participants
|
2 Participants
n=44 Participants
|
2 Participants
n=5 Participants
|
30 Participants
n=20 Participants
|
PRIMARY outcome
Timeframe: Cycle 1 (Up To 28 Days)Population: All phase 1a participants who received at least one dose of LY3405105 in Cycle 1.
A DLT is a clinically significant adverse event that is possibly related to the study drug and fulfils any one of the following criteria using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) v4.0: 1\) Nonhematologic Grade ≥3 toxicity, except nausea, constipation, diarrhoea, vomiting or electrolyte disturbance lasting for \<72 hours and can be controlled with treatment, fatigue/anorexia lasting for \<5 days, transient grade 3 elevations of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), without evidence of other hepatic injury; 2) Total bilirubin \>2×upper limit of normal (ULN) with ALT/AST \>3×ULN in the absence of cholestasis (alkaline phosphatase \<2×ULN); 3) Grade 4 neutropenia \>5 days duration, Any febrile neutropenia, Grade 4 thrombocytopenia of any duration, Grade 3 thrombocytopenia with clinically significant bleeding, Grade 3/4 anemia or any other significant toxicity deemed to be dose limiting by investigators.
Outcome measures
| Measure |
Part A1 Cohort 1 (1 mg, QD)
n=4 Participants
Participants received 1 mg LY3405105 once daily (QD) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 2 (2 mg, QD)
n=4 Participants
Participants received 2 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 3 (4 mg, QD)
n=4 Participants
Participants received 3 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 4 (8 mg, QD)
n=4 Participants
Participants received 8 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 5 (15 mg, QD)
n=5 Participants
Participants received 15 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 6 (30 mg, QD)
n=5 Participants
Participants received 30 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 7 (45 mg, QD)
n=5 Participants
Participants received 45 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 8 (35 mg, QD)
n=3 Participants
Participants received 35 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 9 (25 mg, QD)
n=3 Participants
Participants received 25 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 10 (20 mg, QD)
n=6 Participants
Participants received 20 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 1 (2 mg, TIW)
n=4 Participants
Participants received 2 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 2 (4 mg, TIW)
n=4 Participants
Participants received 4 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 3 (8 mg, TIW)
n=3 Participants
Participants received 8 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Number of Participants With Dose Limiting Toxicities (DLTs)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
3 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline through Measured Progressive Disease (Estimated up to 6 Months)Population: ORR is phase 1b primary outcome measure. Phase 1b of the study is not conducted and no participant enrolled, thus no data collected.
ORR is the best overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Cycle 1 Day 1 (Predose, 1, 2, 4, 6, 8, 24 hours post-dose)Population: All part A1 participants of phase 1a who received at least one dose of LY3405105 and had evaluable PK data.
AUC(0-24) of LY3405105
Outcome measures
| Measure |
Part A1 Cohort 1 (1 mg, QD)
n=4 Participants
Participants received 1 mg LY3405105 once daily (QD) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 2 (2 mg, QD)
n=4 Participants
Participants received 2 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 3 (4 mg, QD)
n=3 Participants
Participants received 3 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 4 (8 mg, QD)
n=4 Participants
Participants received 8 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 5 (15 mg, QD)
n=5 Participants
Participants received 15 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 6 (30 mg, QD)
n=4 Participants
Participants received 30 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 7 (45 mg, QD)
n=5 Participants
Participants received 45 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 8 (35 mg, QD)
n=1 Participants
Participants received 35 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 9 (25 mg, QD)
n=1 Participants
Participants received 25 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 10 (20 mg, QD)
n=4 Participants
Participants received 20 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 1 (2 mg, TIW)
Participants received 2 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 2 (4 mg, TIW)
Participants received 4 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 3 (8 mg, TIW)
Participants received 8 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a (Part A1): Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY3405105
|
12.1 nanograms*hours per milliliter (ng*h/mL)
Geometric Coefficient of Variation 63
|
30.3 nanograms*hours per milliliter (ng*h/mL)
Geometric Coefficient of Variation 140
|
91.3 nanograms*hours per milliliter (ng*h/mL)
Geometric Coefficient of Variation 120
|
102 nanograms*hours per milliliter (ng*h/mL)
Geometric Coefficient of Variation 24
|
159 nanograms*hours per milliliter (ng*h/mL)
Geometric Coefficient of Variation 148
|
775 nanograms*hours per milliliter (ng*h/mL)
Geometric Coefficient of Variation 24
|
1730 nanograms*hours per milliliter (ng*h/mL)
Geometric Coefficient of Variation 104
|
NA nanograms*hours per milliliter (ng*h/mL)
Geometric Coefficient of Variation NA
N=1, Geometric mean and coefficient of variation were not calculated. Individual value reported: 623 ng\*h/mL.
|
NA nanograms*hours per milliliter (ng*h/mL)
Geometric Coefficient of Variation NA
N=1, Geometric mean and coefficient of variation were not calculated. Individual value reported: 599 ng\*h/mL.
|
328 nanograms*hours per milliliter (ng*h/mL)
Geometric Coefficient of Variation 80
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 15 (Predose, 1, 2, 4, 6, 8, 24 hours post-dose)Population: All part A1 participants of phase 1a who received at least one dose of LY3405105 and had evaluable PK data. For Part A1 Cohort 7 (45 mg, QD) and Cohort 9 (25 mg, QD), day 15 PK data was not collected for any participants as study was terminated prior to data collection; thus, zero participants were analysed.
AUC of LY3405105 during one dosing interval of 24 hours \[tau = 24 hours\].
Outcome measures
| Measure |
Part A1 Cohort 1 (1 mg, QD)
n=4 Participants
Participants received 1 mg LY3405105 once daily (QD) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 2 (2 mg, QD)
n=4 Participants
Participants received 2 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 3 (4 mg, QD)
n=3 Participants
Participants received 3 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 4 (8 mg, QD)
n=4 Participants
Participants received 8 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 5 (15 mg, QD)
n=3 Participants
Participants received 15 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 6 (30 mg, QD)
n=4 Participants
Participants received 30 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 7 (45 mg, QD)
Participants received 45 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 8 (35 mg, QD)
n=2 Participants
Participants received 35 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 9 (25 mg, QD)
Participants received 25 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 10 (20 mg, QD)
n=4 Participants
Participants received 20 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 1 (2 mg, TIW)
Participants received 2 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 2 (4 mg, TIW)
Participants received 4 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 3 (8 mg, TIW)
Participants received 8 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a (Part A1): PK: Area Under the Concentration Versus Time Curve During One Dosing Interval [AUC(Tau)] of LY3405105
|
22.6 ng*h/mL
Geometric Coefficient of Variation 37
|
47.4 ng*h/mL
Geometric Coefficient of Variation 115
|
132 ng*h/mL
Geometric Coefficient of Variation 74
|
153 ng*h/mL
Geometric Coefficient of Variation 46
|
208 ng*h/mL
Geometric Coefficient of Variation 25
|
1620 ng*h/mL
Geometric Coefficient of Variation 53
|
—
|
NA ng*h/mL
Geometric Coefficient of Variation NA
N=2, Geometric mean and coefficient of variation were not calculated. Individual values reported: 1760 ng\*h/mL, 3610 ng\*h/mL
|
—
|
NA ng*h/mL
Geometric Coefficient of Variation NA
Due to insufficient quantifiable data, AUC(Tau) couldn't be calculated for any of the participants.
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1 (Predose, 1, 2, 4, 6, 8, 24, 48 hours post-dose)Population: All part A2 participants of phase 1a who received at least one dose of LY3405105 and had evaluable PK data.
AUC(0-∞) of LY3405105.
Outcome measures
| Measure |
Part A1 Cohort 1 (1 mg, QD)
n=3 Participants
Participants received 1 mg LY3405105 once daily (QD) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 2 (2 mg, QD)
n=3 Participants
Participants received 2 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 3 (4 mg, QD)
n=2 Participants
Participants received 3 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 4 (8 mg, QD)
Participants received 8 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 5 (15 mg, QD)
Participants received 15 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 6 (30 mg, QD)
Participants received 30 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 7 (45 mg, QD)
Participants received 45 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 8 (35 mg, QD)
Participants received 35 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 9 (25 mg, QD)
Participants received 25 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 10 (20 mg, QD)
Participants received 20 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 1 (2 mg, TIW)
Participants received 2 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 2 (4 mg, TIW)
Participants received 4 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 3 (8 mg, TIW)
Participants received 8 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a (Part A2): PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY3405105
|
43.5 ng*h/mL
Geometric Coefficient of Variation 88
|
63.3 ng*h/mL
Geometric Coefficient of Variation 48
|
NA ng*h/mL
Geometric Coefficient of Variation NA
N=2, Geometric mean and coefficient of variation were not calculated. Individual values reported: 73.9 ng\*h/mL, 113 ng\*h/mL
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 1 Day 15 (Predose, 1, 2, 4, 6, 8, 24, 48 hours post-dose)Population: All part A2 participants of phase 1a who received at least one dose of LY3405105 and had evaluable PK data.
AUC of LY3405105 during one dosing interval of 48 hours \[tau = 48 hours\].
Outcome measures
| Measure |
Part A1 Cohort 1 (1 mg, QD)
n=4 Participants
Participants received 1 mg LY3405105 once daily (QD) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 2 (2 mg, QD)
n=3 Participants
Participants received 2 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 3 (4 mg, QD)
n=3 Participants
Participants received 3 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 4 (8 mg, QD)
Participants received 8 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 5 (15 mg, QD)
Participants received 15 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 6 (30 mg, QD)
Participants received 30 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 7 (45 mg, QD)
Participants received 45 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 8 (35 mg, QD)
Participants received 35 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 9 (25 mg, QD)
Participants received 25 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 10 (20 mg, QD)
Participants received 20 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 1 (2 mg, TIW)
Participants received 2 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 2 (4 mg, TIW)
Participants received 4 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 3 (8 mg, TIW)
Participants received 8 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a (Part A2): PK: Area Under the Concentration Versus Time Curve During One Dosing Interval [AUC(Tau)] of LY3405105
|
70.5 ng*h/mL
Geometric Coefficient of Variation 81
|
32.6 ng*h/mL
Geometric Coefficient of Variation 201
|
163 ng*h/mL
Geometric Coefficient of Variation 25
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline through Measured Progressive Disease (Up To 349 Days)Population: All phase 1a participants who received at least one dose of LY3405105.
ORR is the best overall tumor response of complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
Outcome measures
| Measure |
Part A1 Cohort 1 (1 mg, QD)
n=4 Participants
Participants received 1 mg LY3405105 once daily (QD) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 2 (2 mg, QD)
n=4 Participants
Participants received 2 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 3 (4 mg, QD)
n=4 Participants
Participants received 3 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 4 (8 mg, QD)
n=4 Participants
Participants received 8 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 5 (15 mg, QD)
n=5 Participants
Participants received 15 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 6 (30 mg, QD)
n=5 Participants
Participants received 30 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 7 (45 mg, QD)
n=5 Participants
Participants received 45 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 8 (35 mg, QD)
n=3 Participants
Participants received 35 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 9 (25 mg, QD)
n=3 Participants
Participants received 25 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 10 (20 mg, QD)
n=6 Participants
Participants received 20 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 1 (2 mg, TIW)
n=4 Participants
Participants received 2 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 2 (4 mg, TIW)
n=4 Participants
Participants received 4 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 3 (8 mg, TIW)
n=3 Participants
Participants received 8 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Objective Response Rate (ORR): Percentage of Participants With a Confirmed Complete Response (CR) or Partial Response (PR)
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
SECONDARY outcome
Timeframe: Baseline through Measured Progressive Disease (Up To 349 Days)Population: All phase 1a participants who received at least one dose of LY3405105.
DCR is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Outcome measures
| Measure |
Part A1 Cohort 1 (1 mg, QD)
n=4 Participants
Participants received 1 mg LY3405105 once daily (QD) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 2 (2 mg, QD)
n=4 Participants
Participants received 2 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 3 (4 mg, QD)
n=4 Participants
Participants received 3 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 4 (8 mg, QD)
n=4 Participants
Participants received 8 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 5 (15 mg, QD)
n=5 Participants
Participants received 15 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 6 (30 mg, QD)
n=5 Participants
Participants received 30 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 7 (45 mg, QD)
n=5 Participants
Participants received 45 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 8 (35 mg, QD)
n=3 Participants
Participants received 35 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 9 (25 mg, QD)
n=3 Participants
Participants received 25 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 10 (20 mg, QD)
n=6 Participants
Participants received 20 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 1 (2 mg, TIW)
n=4 Participants
Participants received 2 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 2 (4 mg, TIW)
n=4 Participants
Participants received 4 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 3 (8 mg, TIW)
n=3 Participants
Participants received 8 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1a: Disease Control Rate (DCR): Percentage of Participants Who Exhibit Stable Disease (SD), Confirmed CR or PR
|
75 Percentage of participants
|
50 Percentage of participants
|
0 Percentage of participants
|
0 Percentage of participants
|
20 Percentage of participants
|
40 Percentage of participants
|
20 Percentage of participants
|
66.7 Percentage of participants
|
33.3 Percentage of participants
|
0 Percentage of participants
|
50 Percentage of participants
|
75 Percentage of participants
|
0 Percentage of participants
|
SECONDARY outcome
Timeframe: Date of Confirmed CR or PR to Date of Objective Progression or Death Due to Any Cause (Estimated up to 12 Months)Population: Zero participants analysed. DoR was not evaluable as there were no participants with CR or PR.
DoR will be calculated only for responders. It is measured from the date of first evidence of a confirmed CR or PR response to the date of first progression of disease or the date of death due to any cause, whichever is earlier.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline to Date of Confirmed CR or PR (Estimated up to 6 Months)Population: Zero participants analysed. TTR was not evaluable as there were no participants with CR or PR.
TTR is defined as the time from the date of start of treatment to the date measurement criteria for confirmed CR or PR (whichever is first recorded) are first met.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 12 Months)Population: PFS is a phase 1b outcome measure. Phase 1b of the study is not conducted and no participant enrolled, thus no data collected.
PFS is defined as the time from the date of start of treatment to the first date of radiologically documented progressive disease or the date of death due to any cause, whichever occurs first.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline to Date of Death from Any Cause (Estimated up to 12 Months)Population: OS is a phase 1b outcome measure. Phase 1b of the study is not conducted and no participant enrolled, thus no data collected.
OS is defined as the time from the date of start of treatment to the date of death due to any cause.
Outcome measures
Outcome data not reported
Adverse Events
Part A1 Cohort 1 (1 mg, QD)
Serious events: 2 serious events
Other events: 4 other events
Deaths: 2 deaths
Part A1 Cohort 2 (2 mg, QD)
Serious events: 1 serious events
Other events: 4 other events
Deaths: 1 deaths
Part A1 Cohort 3 (4 mg, QD)
Serious events: 0 serious events
Other events: 4 other events
Deaths: 2 deaths
Part A1 Cohort 4 (8 mg, QD)
Serious events: 0 serious events
Other events: 4 other events
Deaths: 2 deaths
Part A1 Cohort 5 (15 mg, QD)
Serious events: 0 serious events
Other events: 4 other events
Deaths: 1 deaths
Part A1 Cohort 6 (30 mg, QD)
Serious events: 1 serious events
Other events: 5 other events
Deaths: 1 deaths
Part A1 Cohort 7 (45 mg, QD)
Serious events: 2 serious events
Other events: 5 other events
Deaths: 2 deaths
Part A1 Cohort 8 (35 mg, QD)
Serious events: 3 serious events
Other events: 3 other events
Deaths: 1 deaths
Part A1 Cohort 9 (25 mg, QD)
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
Part A1 Cohort 10 (20 mg, QD)
Serious events: 1 serious events
Other events: 6 other events
Deaths: 1 deaths
Part A2 Cohort 1 (2 mg, TIW)
Serious events: 2 serious events
Other events: 3 other events
Deaths: 2 deaths
Part A2 Cohort 2 (4 mg, TIW)
Serious events: 0 serious events
Other events: 4 other events
Deaths: 3 deaths
Part A2 Cohort 3 (8 mg, TIW)
Serious events: 0 serious events
Other events: 3 other events
Deaths: 3 deaths
Serious adverse events
| Measure |
Part A1 Cohort 1 (1 mg, QD)
n=4 participants at risk
Participants received 1 mg LY3405105 once daily (QD) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 2 (2 mg, QD)
n=4 participants at risk
Participants received 2 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 3 (4 mg, QD)
n=4 participants at risk
Participants received 3 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 4 (8 mg, QD)
n=4 participants at risk
Participants received 8 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 5 (15 mg, QD)
n=5 participants at risk
Participants received 15 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 6 (30 mg, QD)
n=5 participants at risk
Participants received 30 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 7 (45 mg, QD)
n=5 participants at risk
Participants received 45 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 8 (35 mg, QD)
n=3 participants at risk
Participants received 35 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 9 (25 mg, QD)
n=3 participants at risk
Participants received 25 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 10 (20 mg, QD)
n=6 participants at risk
Participants received 20 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 1 (2 mg, TIW)
n=4 participants at risk
Participants received 2 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 2 (4 mg, TIW)
n=4 participants at risk
Participants received 4 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 3 (8 mg, TIW)
n=3 participants at risk
Participants received 8 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
General disorders
Mucosal inflammation
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Hepatobiliary disorders
Bile duct stenosis
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Anal abscess
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Coronavirus infection
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Ophthalmic herpes zoster
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Platelet count decreased
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Vascular disorders
Hypotension
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
Other adverse events
| Measure |
Part A1 Cohort 1 (1 mg, QD)
n=4 participants at risk
Participants received 1 mg LY3405105 once daily (QD) orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 2 (2 mg, QD)
n=4 participants at risk
Participants received 2 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 3 (4 mg, QD)
n=4 participants at risk
Participants received 3 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 4 (8 mg, QD)
n=4 participants at risk
Participants received 8 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 5 (15 mg, QD)
n=5 participants at risk
Participants received 15 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 6 (30 mg, QD)
n=5 participants at risk
Participants received 30 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 7 (45 mg, QD)
n=5 participants at risk
Participants received 45 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 8 (35 mg, QD)
n=3 participants at risk
Participants received 35 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 9 (25 mg, QD)
n=3 participants at risk
Participants received 25 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A1 Cohort 10 (20 mg, QD)
n=6 participants at risk
Participants received 20 mg LY3405105 QD orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 1 (2 mg, TIW)
n=4 participants at risk
Participants received 2 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 2 (4 mg, TIW)
n=4 participants at risk
Participants received 4 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
Part A2 Cohort 3 (8 mg, TIW)
n=3 participants at risk
Participants received 8 mg LY3405105 TIW orally on a 28-day cycle until confirmed progressive disease, unacceptable toxicity, or discontinuation for any other reason.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
75.0%
3/4 • Number of events 7 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
50.0%
2/4 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
60.0%
3/5 • Number of events 6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
40.0%
2/5 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
2/6 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
50.0%
2/4 • Number of events 4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Ear and labyrinth disorders
Deafness
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Blood and lymphatic system disorders
Neutrophilia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Eye disorders
Dry eye
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Eye disorders
Periorbital oedema
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Eye disorders
Vision blurred
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Abdominal distension
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
2/6 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Abdominal pain
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
40.0%
2/5 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
66.7%
2/3 • Number of events 4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
66.7%
2/3 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
66.7%
2/3 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Anal haemorrhage
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
50.0%
2/4 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
50.0%
2/4 • Number of events 7 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
80.0%
4/5 • Number of events 9 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
80.0%
4/5 • Number of events 5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
100.0%
3/3 • Number of events 11 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
66.7%
2/3 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
50.0%
3/6 • Number of events 4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
50.0%
2/4 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
2/6 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Gastric haemorrhage
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Gingival pain
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Hypoaesthesia oral
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Lip pain
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
40.0%
2/5 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
60.0%
3/5 • Number of events 4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
66.7%
2/3 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
50.0%
3/6 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
75.0%
3/4 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
60.0%
3/5 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
40.0%
2/5 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
66.7%
2/3 • Number of events 7 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
General disorders
Asthenia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
75.0%
3/4 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
General disorders
Chest pain
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
General disorders
Fatigue
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
50.0%
2/4 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
60.0%
3/5 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
40.0%
2/5 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 8 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
50.0%
3/6 • Number of events 4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
General disorders
Gait disturbance
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
General disorders
Illness
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
General disorders
Influenza like illness
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
General disorders
Mucosal inflammation
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
40.0%
2/5 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
General disorders
Oedema peripheral
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
50.0%
2/4 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
General disorders
Pain
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
General disorders
Pyrexia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Hepatobiliary disorders
Bile duct stenosis
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Biliary tract infection
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Gingivitis
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Ophthalmic herpes zoster
|
25.0%
1/4 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Oral infection
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Postoperative wound infection
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Rash pustular
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Sepsis
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Infections and infestations
Vulvovaginal mycotic infection
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Amylase increased
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Alanine aminotransferase increased
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
66.7%
2/3 • Number of events 5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Aspartate aminotransferase increased
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
66.7%
2/3 • Number of events 5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
50.0%
2/4 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Blood alkaline phosphatase
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Electrocardiogram qt prolonged
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Lipase increased
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Platelet count decreased
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
40.0%
2/5 • Number of events 7 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
100.0%
3/3 • Number of events 11 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Troponin i increased
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
Weight decreased
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Investigations
White blood cell count decreased
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
60.0%
3/5 • Number of events 4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
66.7%
2/3 • Number of events 4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
2/6 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
40.0%
2/5 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
66.7%
2/3 • Number of events 4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
40.0%
2/5 • Number of events 3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Joint range of motion decreased
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour associated fever
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Nervous system disorders
Ataxia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Nervous system disorders
Headache
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
2/6 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Nervous system disorders
Nystagmus
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Nervous system disorders
Seizure
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Psychiatric disorders
Depressed mood
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Psychiatric disorders
Depression
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Renal and urinary disorders
Chromaturia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
40.0%
2/5 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
40.0%
2/5 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Erythema multiforme
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Pain of skin
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
16.7%
1/6 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
33.3%
1/3 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Skin irritation
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
20.0%
1/5 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Vascular disorders
Embolism
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Vascular disorders
Hot flush
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Vascular disorders
Hypotension
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
40.0%
2/5 • Number of events 2 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
|
Vascular disorders
Orthostatic hypotension
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
25.0%
1/4 • Number of events 1 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/5 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/6 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/4 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
0.00%
0/3 • Baseline to Follow-up (Up To 690 Days)
All phase 1a participants who received at least one dose of LY3405105. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60